Isotechnika chops staff, names acting CEO in restructuring

Canada's Aurinia Pharmaceuticals, formerly called Isotechnika, is shaking up its executive team and laying off staffers. The biotech says that Richard Glickman is now the acting CEO, replacing Robert Foster, who will take the CSO's job. About a third of the company's staff is being axed while it reduces the size of its offices by half. Release

Suggested Articles

When it’s time to go public, most biotech companies for the Nasdaq. Not so for SQZ Biotech, which raised $71 million in its NYSE debut.

The saga of COVID antibody R&D continues as the REGN-COV2 antibody cocktail used by President Donald Trump has been hit by safety concerns.

A Dartmouth-led team proposed a method for targeting and inhibiting the most aggressive cells in breast tumors to improve responses to chemotherapy.